USOR 24155 - Ph3 study of mFOLFOX6 as FIL treatment in subjects with colorectal cancer

A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Disease Types: Colorectal

Available at: Arlington Heights, Chicago, Niles